Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer

Completed · Phase 1

Conditions studied: Cancer

In brief

This is an open-label, multicenter, ascending multiple dose study of REGN1400 alone and in combination with erlotinib or cetuximab administered to patients with certain types of cancer.

Key facts

Study ID

NCT01727869

Run by

Regeneron Pharmaceuticals

People needed

56

Starts

2012-10-01

Expected to finish

2015-01-01

Last updated by the study team

2015-04-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Santa Monica, California, United States
• Study site — Atlanta, Georgia, United States
• Study site — Detroit, Michigan, United States
• Study site — Buffalo, New York, United States
• Study site — New York, New York, United States
• Study site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.